NO20070127L - Fremgangsmate for behandling av granuloma annulare eller sarkoid - Google Patents

Fremgangsmate for behandling av granuloma annulare eller sarkoid

Info

Publication number
NO20070127L
NO20070127L NO20070127A NO20070127A NO20070127L NO 20070127 L NO20070127 L NO 20070127L NO 20070127 A NO20070127 A NO 20070127A NO 20070127 A NO20070127 A NO 20070127A NO 20070127 L NO20070127 L NO 20070127L
Authority
NO
Norway
Prior art keywords
sarcoid
procedure
treatment
granuloma
annular
Prior art date
Application number
NO20070127A
Other languages
English (en)
Norwegian (no)
Inventor
Bernard S Goffe
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of NO20070127L publication Critical patent/NO20070127L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2845—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta2-subunit-containing molecules, e.g. CD11, CD18
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2821—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against ICAM molecules, e.g. CD50, CD54, CD102
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
NO20070127A 2004-06-09 2007-01-08 Fremgangsmate for behandling av granuloma annulare eller sarkoid NO20070127L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US57876804P 2004-06-09 2004-06-09
US57909604P 2004-06-10 2004-06-10
PCT/US2005/020342 WO2005123777A2 (fr) 2004-06-09 2005-06-08 Procede de traitement du granulome annulaire ou sarcoide

Publications (1)

Publication Number Publication Date
NO20070127L true NO20070127L (no) 2007-01-08

Family

ID=35355731

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20070127A NO20070127L (no) 2004-06-09 2007-01-08 Fremgangsmate for behandling av granuloma annulare eller sarkoid

Country Status (11)

Country Link
US (1) US7396530B2 (fr)
EP (1) EP1756163A2 (fr)
JP (1) JP2008507592A (fr)
AU (1) AU2005254980A1 (fr)
BR (1) BRPI0511305A (fr)
CA (1) CA2568570A1 (fr)
IL (1) IL179557A0 (fr)
MX (1) MXPA06014354A (fr)
NO (1) NO20070127L (fr)
RU (1) RU2006146939A (fr)
WO (1) WO2005123777A2 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5105578B2 (ja) 2003-11-05 2012-12-26 サーコード バイオサイエンス インコーポレイテッド 細胞接着のモジュレーター
MX2010004281A (es) 2007-10-19 2010-09-10 Sarcode Corp Composiciones y metodos para el tratamiento de la retinopatia diabetica.
ES2763703T3 (es) * 2008-04-15 2020-05-29 Sarcode Bioscience Inc Antagonistas de LFA-1 tópicos utilizados en el tratamiento localizado de trastornos inmunes
CA2881966C (fr) 2012-08-24 2020-10-06 The Regents Of The University Of California Anticorps et vaccins utilisables en vue du traitement de cancers ror1 et de l'inhibition de la metastase
EP3474854A4 (fr) 2016-06-27 2020-02-19 The Regents of The University of California Associations médicamenteuses pour le traitement du cancer
RU2671516C1 (ru) * 2018-01-10 2018-11-01 Федеральное государственное бюджетное военное образовательное учреждение высшего образования Военно-медицинская академия имени С.М. Кирова Министерства обороны Российской Федерации (ВМедА) Способ лечения кольцевидной гранулемы

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5002869A (en) 1987-11-02 1991-03-26 Dana-Farber Cancer Institute Monoclonal antibody specific to a novel epitope of the LFA-1 antigen of human T lymphocytes
US5071964A (en) 1988-05-04 1991-12-10 Dana-Farber Cancer Institute, Inc. Protein micelles
US5147637A (en) 1988-06-07 1992-09-15 The Rockefeller University Method of inhibiting the influx of leukocytes into organs during sepsis or other trauma
NO900155L (no) 1989-01-24 1990-07-25 Molecular Therapeutics Inc Et opploeselig molekyl som er relatert til, men forskjellig fra icam-1.
CA2008368C (fr) 1989-01-24 2003-04-08 Jeffrey Greve Molecule soluble apparentee a l'icam-i mais distincte
CA2011633C (fr) 1989-03-09 2007-05-15 Timothy A. Springer Molecules d'adhesion intercellulaire (icam-2) et ses liquides
JPH04505009A (ja) 1989-03-09 1992-09-03 ダナ・ファーバー・キャンサー・インスティチュート クローニングｌｆａ―１
AU5568290A (en) 1989-04-28 1990-11-29 Baylor College Of Medicine Method of suppressing hiv infection
ES2095876T3 (es) 1989-06-02 1997-03-01 Univ Johns Hopkins Med Anticuerpos monoclonales contra la cadena beta de receptores de adhesion de leucocitos; procedimiento de produccion de estos anticuerpos y utilizacion
US5324510A (en) 1989-09-01 1994-06-28 Boehringer Ingelheim Pharmaceuticals, Inc. Use of antibodies to intercellular adhesion molecule-1 (ICAM-1) in the treatment of asthma
GB9009549D0 (en) 1990-04-27 1990-06-20 Celltech Ltd Recombinant antibody and method
GB9009548D0 (en) 1990-04-27 1990-06-20 Celltech Ltd Chimeric antibody and method
WO1991018011A1 (fr) 1990-05-15 1991-11-28 Swinburne Limited Inhibition d'adhesion cellulaire a l'aide de peptides analogues a la molecule-1-d'adhesion intercellulaire et/ou d'analogues de ces peptides
GB9115364D0 (en) 1991-07-16 1991-08-28 Wellcome Found Antibody
AU667487B2 (en) 1991-10-01 1996-03-28 General Hospital Corporation, The Preventing allograft rejection with antibodies to adhesion molecules
JP3679112B2 (ja) 1991-10-04 2005-08-03 アメリカ合衆国 細胞接着分子の遮断による眼の炎症の治療
US5932448A (en) 1991-11-29 1999-08-03 Protein Design Labs., Inc. Bispecific antibody heterodimers
GB2266664A (en) 1992-04-28 1993-11-10 Pierre Francois Piguet Monoclonal antibodies for prophylaxis and treatment of pulmonary fibrosis
AU687755B2 (en) 1992-08-21 1998-03-05 Genentech Inc. Method for treating an LFA-1-mediated disorder
DK0941344T3 (da) 1996-11-27 2004-09-27 Genentech Inc Humaniserede anti-CD11a-antistoffer
US6037454A (en) 1996-11-27 2000-03-14 Genentech, Inc. Humanized anti-CD11a antibodies
FR2763072B1 (fr) 1997-05-12 1999-11-05 Pasteur Merieux Serums Vacc Utilisation d'un anticorps monoclonal anti-lfa1 en transplantation renale
CO5140104A1 (es) * 1999-02-16 2002-03-22 Novartis Ag Derivados de mevinolina y preparacion farmaceuticas que los contienen
PE20020420A1 (es) * 2000-10-02 2002-06-27 Novartis Ag Derivados de diazacicloalcanodiona como antagonistas del antigeno asociado a la funcion del linfocito-1 (lfa-1)

Also Published As

Publication number Publication date
EP1756163A2 (fr) 2007-02-28
BRPI0511305A (pt) 2007-12-04
AU2005254980A1 (en) 2005-12-29
WO2005123777A3 (fr) 2006-03-02
WO2005123777A2 (fr) 2005-12-29
IL179557A0 (en) 2007-05-15
US7396530B2 (en) 2008-07-08
CA2568570A1 (fr) 2005-12-29
US20060013818A1 (en) 2006-01-19
JP2008507592A (ja) 2008-03-13
RU2006146939A (ru) 2008-07-20
MXPA06014354A (es) 2007-02-19

Similar Documents

Publication Publication Date Title
WO2007143600A3 (fr) Inhibiteurs de la sheddase combinés avec des substances immunothérapeutiques se liant à cd30 destinés au traitement de maladies associées à cd30
BR0314760A (pt) Compostos orgânicos
BRPI0510274A (pt) epìtopos relacionados à doença celìaca
NO20070906L (no) Fremgangsmate for behandling av hyperfosfatanemi ved anvendelse av lantanhydroksykarbonat
WO2009064388A3 (fr) Inhibiteurs de la méthionine aminopeptidase humaine 1 et procédés de traitement de troubles
BRPI0416628A (pt) uso de compostos orgánicos
WO2008050329A3 (fr) NOUVEAUX ARNsi ET PROCÉDÉS D'UTILISATION DE CEUX-CI
NO20080745L (no) Nye peptider for anvendelse i behandling av fedme
WO2007128802A3 (fr) Utilisation de flibansérine pour le traitement des troubles de la libido post-ménopausiques
NO20091296L (no) Fremgangsmate for behandling av slag med trombolytisk middel
NO20083561L (no) Forbindelser for behandling av inflammatoriske forstyrrelser
MA34133B1 (fr) Composes pour inhibiteurs de l'immunoproteasome
NO20083836L (no) N-hydroksyakrylamidforbindelser
MA56187B1 (fr) Traitements de l'angio-oedème héréditaire
EA201490277A1 (ru) Ингибиторы кинуренин-3-монооксигеназы, фармацевтические композиции и способы их применения
SG166820A1 (en) Use of flibanserin for the treatment of pre-menopausal sexual desire disorders
BRPI0519124A2 (pt) composto, mÉtodo para tratar, prevenir ou melhorar obesidade e doenÇas relacionadas e/ou sintomas das mesmas, composiÇço farmacÊutica, uso de composto, e, combinaÇço
NO20076245L (no) Anvendelse av TFPI for a behandle alvorlige bakterieinfeksjoner
NO20074252L (no) Forbindelser og anvendelser derav
WO2006106311A3 (fr) Methodes de traitement combinees
NO20061818L (no) Fremgangsmate for a inhibere remnant lipoproteinproduksjon
DK1778837T3 (da) Behandling af neurodegenerative sygdomme ved anvendelse af SCD4-inhibitorer
BRPI0617655A2 (pt) composto ou um sal farmaceuticamente aceitável do mesmo, ou um isômero óptico do mesmo, uso de um composto, e, formulação farmacêutica
NO20070061L (no) 3-beta-D-ribofuranosyltiazolo[4,5-d]pyridiminnukleosider og anvendelser derav
WO2007019153A3 (fr) Methodes de traitement de l'hypertension

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application